BEAM-101
- Generic Name
- BEAM-101
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Beam Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05456880
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital, Atlanta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath